CTLA4 and cancer: The emergence of cancer immunotherapeutics that target cancer-related T cell dysregulation such as the currently approved immune checkpoint inhibitors based on PD1, PD-L1, and CTLA-4 have encouraged the investigation of additional checkpoint pathways as immunotherapeutic targets.